

[Redacted]
To: [Redacted] >
cc:
12/04/2005 11:57 AM Subject: Re: PROTOPIC

Dear [Redacted]
Thank you for your letter of 11th April 2005 in which you advised of the withdrawal of your application to register Protopic. Our records will be updated.

You also enclosed a separate letter on your potential resubmission.

Here are some comments:

New studies: these will help to define conventional and general safety but not specific risks. For example, studies on photodamaged skin, adequately power by size and by duration to detect various malignancies. You are conducting longer term epidemiological studies to attend to this and these data would be of interest.

Skin selectivity statement: this is false and misleading. the local dose is high and it risks local infections and tumours and, I presume, solar keratoses. Moreover, it relies on spurious toxicokinetic and pharmacokinetic arguments. The high local exposure to the immune system is why it works and may also be why Protopic might be a problem.

Who can prescribe: A non-significant change that has no practical effect.

Comparative trials: the text will be informed by the outcome of the evaluation.

Change of terminology: the evaluator will be asked to comment. I assume that both sets of terminology are compatible with CIOMS data presentation requirements.

Yours sincerely,

[Redacted signature]

[Redacted line]



To: [Redacted]
cc:
Subject: PROTOPIC
11/04/2005 09:08 AM

Dear [Redacted]

Thank you for your advice with PROTOPIC. I have had contact with [Redacted] and we have together decided to withdraw the file. I will write to you at DSEB today about this

Best Regards,

[Redacted signature]

Confidentiality Notice: This document is J&J Proprietary. You may forward this document within J&J on a need to know basis. You may not forward this onto the Internet without the author's permission. This e-mail transmission may contain confidential or legally privileged information that is

JS

intended

only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that J&J can arrange for proper delivery, and then please delete the message from your inbox.

Visit the J&J Website at <http://www.jnj.com>

Ref: RA.05.173
File Ref: TAC 01 04



JANSSEN-CILAG ⁸⁷

A Johnson & Johnson Company

11 April 2005

[REDACTED]
Drug Safety and Evaluation Branch
136 Narrabundah Lane
Symonston ACT 2609



Dear [REDACTED]

PROTOPIC (Tacrolimus) Ointment. Applic No. 2004/266/5

Janssen Cilag wishes to advise their decision to **withdraw** this file, following receipt of your advice

Yours Sincerely,

[REDACTED]

[REDACTED]

Biotechnology Manager, Janssen Cilag

*Noted.
Premier has been
withdrawn.*

[REDACTED]
12 APR 2005

Head C&S

Telephone: (61 2) 8875 3333
Fax: (61 2) 8875 3300
Toll Free: 1800 226 334

Locked Bag 2070, North Ryde NSW 1670, Australia
1-5 Khartoum Road, North Ryde NSW 2113, Australia
ABN 47000 129 975



Quality Assured Company

ISO 9001